Form 4: Xeris Biopharma Holdings Director John P. Schmid Reports Stock Purchase
SEC Form 4 Filing
Director John P. Schmid of Xeris Biopharma Holdings, Inc. reports purchasing 4,515 shares of common stock at $2.2474 per share on August 12, 2024.
Summary
- On August 12, 2024, John P. Schmid, a director of Xeris Biopharma Holdings, Inc., purchased 4,515 shares of common stock.
- The purchase price was $2.2474 per share.
- Following the transaction, Schmid directly owns 113,159 shares of common stock.
- Schmid also indirectly owns 25,200 shares through The Schmid Family Trust dated August 15, 2017.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine transaction. Insider buying can be seen as a positive signal, but the quantity is not significant enough to drastically alter sentiment.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, which is a routine part of corporate governance and transparency requirements for company insiders.
Stakeholder Impact
- The stock purchase could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| August 15, 2017 | Date of The Schmid Family Trust |
| 08/12/2024 | Date of stock purchase transaction |
| 08/13/2024 | Date of signature by Attorney-in-Fact |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.